Adam Wolfe

Has grant

Assistant Professor

University of Arkansas for Medical Sciences

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Adam Wolfe is an Assistant Professor at the University of Arkansas for Medical Sciences, United States. His research focuses on pancreatic cancer, specifically examining the RAS-RAF-miR-296-3p signaling axis, nutrient scavenging in nutrient-deprived conditions, and the relationship between neutrophil-to-lymphocyte ratios and radiation prognosis. Additionally, he investigates therapeutic efficacy improvements through altered gemcitabine scheduling and compares treatment outcomes in neoadjuvant therapies for pancreatic ductal adenocarcinoma.

Recent Grants

Grant: Close

Development of a miRNA Signature to Personalize Radiation Therapy in PDAC

Open Date: 2019-07-01

Close Date: 2021-06-30

Articles (8)

Year:

2024

Year:

2024

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (3)

Xueliang Pan

Associate Professor - clinical

Ohio State University

UNITED STATES

View details

Eric D. Miller

The Ohio State University Comprehensive Cancer Center

UNITED STATES

View details

Terence Williams

City Of Hope National Medical Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Adam Wolfe

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (8)

RAS-RAF-miR-296-3p signaling axis increases Rad18 expression to augment radioresistance in pancreatic and thyroid cancers

Nutrient scavenging-fueled growth in pancreatic cancer depends on caveolae-mediated endocytosis under nutrient-deprived conditions

Increasing neutrophil-to-lymphocyte ratio following radiation is a poor prognostic factor and directly correlates with splenic radiation dose in pancreatic cancer

Morphologic changes associated with neoadjuvant-treated pancreatic ductal adenocarcinoma and comparison of two tumor regression grading systems

Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic Cancer

Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection

Clinical Outcomes and Multidisciplinary Patterns of Failure for Olfactory Neuroblastoma: The Ohio State Experience

Erratum: Clinical Outcomes and Multidisciplinary Patterns of Failure for Olfactory Neuroblastoma: The Ohio State Experience

Collaborators (3)

Xueliang Pan

Eric D. Miller

Terence Williams

Make your next move.